Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Retatrutide is drawing attention after new trial data showed dramatic weight loss and pain relief. Here’s how the ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Though it hasn't even wrapped up clinical trials, the weight loss drug retatrutide already has a cult following.

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...